Web-based symptom support after radioactive iodine for differentiated thyroid cancer
Official title: A Pilot Randomized Controlled Trial of the Use of a Website About Radioactive Iodine Symptom Management in Patients With Thyroid Cancer
Run by Georgetown University · NCT06853925 · Data updated 2026-11-12
This will test a four-week web program called RAI Support to help adults treated with radioactive iodine for differentiated thyroid cancer manage symptoms and improve overall quality of life compared with usual online information.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 88 (estimated) |
| Sponsor | Georgetown University Academic / other |
| Locations | 1 site (Washington D.C., District of Columbia) |
| Status | Recruiting |
| Started | October 2, 2025 |
| Main results expected | February 2027 |
| Study ends | February 2027 |
| Registry record updated | January 16, 2026 |
| Trial ID | NCT06853925 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with papillary or follicular thyroid cancer who had radioactive iodine within the past three years, report mild-to-moderate RAI-related symptoms, can consent in English, and have internet access are ideal candidates.
✕Probably not a fit
People with severe cognitive or psychiatric impairment, major hearing problems, no internet access, non-English speakers, or those whose RAI was more than three years ago may not receive benefit from this online program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with differentiated (papillary or follicular) thyroid cancer who received radioactive iodine within the past three years and have mild-to-moderate symptoms are assigned to either RAI Support or a publicly available informational website for four weeks. RAI Support provides educational resources and symptom-management strategies through an online platform accessible by computer, tablet, or smartphone. The study measures usability and health-related quality of life to see if the web program improves overall well-being compared with treatment as usual. This pilot work focuses on feasibility and preliminary benefit among English-speaking participants with internet access.
Why it matters
Potential benefit: If successful, the program could give thyroid cancer survivors an easy-to-use online toolkit to reduce symptoms and improve daily well-being after radioactive iodine.
How similar studies have gone: Internet-based symptom-management programs for cancer patients have shown mixed but promising results, while RAI-specific digital interventions remain relatively untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 or older (papillary or follicular carcinoma) * Diagnosed with differentiated thyroid cancer * Received radioactive iodine (RAI) treatment less than or equal to three years ago. * Mild to moderate symptoms of RAI * Able to provide informed consent in English * Access to a computer, tablet, or smartphone with internet connectivity Exclusion Criteria: * A condition that precludes providing informed consent or completing study procedures (cognitive or psychiatric condition, hearing problems) as identified by the patient's physician or as assessed by a trained study team member.
Where it's running
-
Georgetown University
Washington D.C., District of Columbia, United States Recruiting
Study contacts
- Principal investigator: Alaina Carr, PhD — Georgetown University
- Study coordinator: Alaina L Carr, PhD
- Email: cancercarestudy@georgetown.edu
- Phone: 202-687-0958
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
EMDR group program with optional individual EMDR for people with cancer
This project will try EMDR group therapy plus optional individual EMDR to reduce PTSD symptoms and psychological distress in people diagnosed with cancer.
-
Neoadjuvant treatment response in locally advanced thyroid cancer
This study will test whether neoadjuvant therapies can safely shrink locally advanced thyroid cancers and improve surgical outcomes for patients who then undergo thyroidectomy.
-
Hybrid endoscopic hemithyroidectomy plus targeted radiofrequency ablation for bilateral papillary thyroid cancer
It will test whether removing the larger tumor with a gas-less axillo-breast endoscopic hemithyroidectomy and treating a small opposite-side tumor with same-session radiofrequency ablation preserves thyroid function and controls cancer in adults with bilateral papillary thyroid carcinoma.
-
Dual-channel near-infrared imaging with AI to locate parathyroid glands
This project tests PTFinder, a device that uses near-infrared autofluorescence and AI to make removed thyroid or parathyroid tissue glow so doctors can quickly and accurately identify parathyroid glands in adults having thyroid or parathyroid surgery.
-
New endoscopic surgery technique for thyroid tumors
This study is testing a new way to perform thyroid surgery using a small dual-port technique to see if it is safer and more effective than the traditional open surgery for people with thyroid tumors.
-
Immediate biopsy versus active ultrasound monitoring for suspicious thyroid nodules
This will try immediate biopsy versus careful ultrasound monitoring to see which causes less anxiety and better thyroid-related quality of life for adults with newly found suspicious thyroid nodules (TI‑RADS 4–5) that are 2 cm or smaller.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.